|Jump to:||Authorized Access|||||Attribution|||||Authorized Requests|
- Study Description
The Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium is an international effort to discover risk loci for prostate cancer. The following de novo genotyping was performed. The OMNI 2.5M genotyping was conducted for 977 prostate cancer cases from UKGPCS. The Exome SNP array genotyping was conducted for 4741 subjects from UKGPCS. The iCOGs genotyping was conducted for 10366 subjects which includes the Multiethnic Cohort (n=1648) and UKGPCS (n=8718). Below is a description of these studies:
UK Genetic Prostate Cancer Study (UKGPCS):
UKGPCS was first established in 1993 and is the largest prostate cancer study of its kind in the UK, involving nearly 189 hospitals. We are based at The Institute of Cancer Research in Sutton, Surrey, and collaborate with the Royal Marsden NHS Foundation Trust.
Our aim is to find genetic changes which are associated with prostate cancer risk.
Our target is to recruit 26,000 gentlemen into the UKGPCS by 2017. Men are eligible to take part if they fit into at least one of the following groups:
- They have been diagnosed with prostate cancer at 60 years of age or under (up to their 61st birthday).
- They have been diagnosed with prostate cancer and a first, second or third degree relative where at least one of these men were diagnosed with prostate cancer at 65 years of age or under.
- They are affected and have 3 or more cases of prostate cancer on one side of their family.
- They are a prostate cancer patient at the Royal Marsden NHS Foundation Trust.
We have to date recruited around 16,000 men on whom we have germline DNA and clinical data at diagnosis.
Multiethnic Cohort (MEC):
The MEC Study is a population-based prospective cohort study that was initiated between 1993 and 1996 and includes subjects from various ethnic groups - African Americans and Latinos primarily from Californian (great Los Angeles area) and Native Hawaiians, Japanese-Americans, and European Americans primarily from Hawaii. State drivers' license files were the primary sources used to identify study subjects in Hawaii and California. Additionally, in Hawaii, state voter's registration files were used, and, in California, Health Care Financing Administration (HCFA) files were used to identify additional African American men. All participants (n=215,251) returned a 26-page self-administered baseline questionnaire that obtained general demographic, medical and risk factor information. In the cohort, incident cancer cases are identified annually through cohort linkage to population-based cancer Surveillance, Epidemiology, and End Results (SEER) registries in Hawaii and Los Angeles County as well as to the California State cancer registry. Information on stage and grade of disease are also obtained through the SEER registries. Blood sample collection in the MEC began in 1994 and targeted incident prostate cancer cases and a random sample of study participants to serve as controls for genetic analyses.
Acknowledgement Statement - Funding:
This work was supported by the GAME-ON U19 initiative for prostate cancer (ELLIPSE): U19 CA148537.
We would like to acknowledge the NCRN nurses and Consultants for their work in the UKGPCS study. We thank all the patients who took part in this study. This work was supported by Cancer Research UK (grant numbers C5047/A7357, C1287/A10118, C1287/A5260, C5047/A3354, C5047/A10692, C16913/A6135 and C16913/A6835). We would also like to thank the following for funding support: Prostate Research Campaign UK (now Prostate Cancer UK), The Institute of Cancer Research and The Everyman Campaign, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.
The MEC was supported by NIH grants CA63464, CA54281 and CA098758.
- Authorized Access
- Publicly Available Data (Public ftp)
- Molecular Data
Type Source Platform Number of Oligos/SNPs SNP Batch Id Comment Targeted Genotyping Illumina HumanOmni2.5-8 (Omni2.5) 2379855 N/A Targeted Genotyping Illumina Human Exome BeadChip v1.2 N/A N/A Targeted Genotyping Illumina iCOGS Array N/A N/A
- Selected publications
- Diseases/Traits Related to Study (MESH terms)
- Primary Phenotype: Prostatic Neoplasms
- Links to Related Resources
- Authorized Data Access Requests
- Study Attribution